Prolacta Bioscience, Inc. (Prolacta) is the pioneer in standardized human milk-based nutritional products for premature infants in the neonatal intensive care unit (NICU). Prolacta believes that there is no adequate replacement for human breast milk and, as such, we believe infant nutritional products should be human milk-based. As a privately held, for-profit and scientifically driven company, committed to improving premature infant nutrition, we are using human milk to change the standard of care in the NICU. Mothers who have a surplus of breast milk can help save the country’s most fragile infants by donating their extra breast milk through one of Prolacta’s affiliate milk banks.

Company Mission

Prolacta develops clinically proven, high-value products derived from human milk that are designed to meet the needs of extremely premature infants in the Neonatal Intensive Care Unit.

Company Overview

Prolacta Bioscience is a privately held, life sciences company dedicated to improving the quality of life in the most fragile infants through the harmony of nature and science. We create specialty formulations made from human milk for the nutritional needs of premature infants in neonatal intensive care units (NICU). These formulations are sold to NICUs around the country.

Prolacta developed the first large scale human milk processing facility in the world. Using state-of-the-art formulation, pasteurization and filling processes, we formulate human milk to an exact standard to meet the needs of very low birth weight babies during the first 30 days of life.

Prolacta is committed to supporting research in the study of human milk and premature infant nutrition in order to make a difference in the lives of the most fragile premature babies.